Evaluation of topical gels containing ketorolac tromethamine on inflammation and hyperalgesia in rats
- Publication Type:
- Journal Article
- Citation:
- Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10 (5), pp. 323 - 326
- Issue Date:
- 2011-10-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| Galley Proof-Pabreja and Dua_AIAAMC.pdf | Published Version | 253.92 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Over recent years, non-steroidal anti-inflammatory drugs (NSAIDs) have been increasingly introduced as topical preparations as they are simple to apply and deliver high drug concentrations locally with limited side effects. Ketorolac trometamol (KT), a potent COX-2 inhibitor, produces typical side effects of NSAIDs when given orally and systemically. Hence the present investigation encompasses the development of topical formulations employing different dermatological bases and evaluated for its efficacy and safety. Standard procedures were followed to test the anti-inflammatory and antihyperalgesic effects in male Wistar albino rats. Amongst the various semisolid formulations, the formulation containing hydroalcoholic carbopol gel base (KT 1) was found to be significantly (p < 0.05) more effective in inhibiting hyperalgesia associated with inflammation (79.69±1.51 after 5 h of carrageenan administration) as compared to formulation containing plain carbopol gel base (68.75±2.76) and PEG base 73.44±1.23. This demonstrates the suitability of carbopol gel base as an ideal dermatological base for ketorolac trometamol topical formulation and thus providing an ample credence for better therapeutic efficacy. © 2011 Bentham Science Publishers.
Please use this identifier to cite or link to this item: